Po Hien Ear, PhD (@pohienear) 's Twitter Profile
Po Hien Ear, PhD

@pohienear

U Iowa Surgery Asst Professor, Neuroendocrine Tumors, Rare cancers, #nanets2024 Symposium Chair, sharing own thoughts

ID: 1179967853753257984

calendar_today04-10-2019 03:54:21

2,2K Tweet

721 Followers

761 Following

Endocrine Today (@endocrinetoday) 's Twitter Profile Photo

💡 Genetic screening for MEN1 should be conducted for 🎯 People diagnosed with clinical or familial MEN1 🎯 Anyone with a first-degree relative 🎯 Those with clinical manifestations of MEN1 AACE Jaydira Del Rivero, MD NIH @CedarSinai HemOnc Today healio.com/news/endocrino…

Udhayvir Grewal (@ugrewalmd) 's Twitter Profile Photo

If you’re looking for a great review on approach to diagnosing and treating patients with Pheo and Para- look no further. Hussam Alkaissi Jaydira Del Rivero, MD #KarelPacak et al discuss the latest in the care of patients with Pheo/Para in this excellent review 🔥 Pheo Para Alliance Neuroendocrine Cancer Foundation

If you’re looking for a great review on  approach to diagnosing and treating patients with Pheo and Para- look no further. 
<a href="/AlkaissiHussam/">Hussam Alkaissi</a> <a href="/JaydiDelRivero/">Jaydira Del Rivero, MD</a> #KarelPacak et al discuss the latest in the care of patients with Pheo/Para in this excellent review 🔥 <a href="/PheoPara/">Pheo Para Alliance</a> <a href="/NCFCancer/">Neuroendocrine Cancer Foundation</a>
Heloisa Soares MD (@helops79) 's Twitter Profile Photo

Big news for the #NETs community! ASCO has released its first guideline to help oncologists manage symptoms of GEP NETS. A major step forward in improving quality of life of patients. dailynews.ascopubs.org/do/asco-releas… congrats Jaydira Del Rivero, MD and all!

ASCO (@asco) 's Twitter Profile Photo

ICYMI: We released our 1st guideline to aid oncologists in managing symptoms of GEP-NETs—complex diseases that can take a toll on patient function & quality of life. #ASCODailyNews has more, including comments from Expert Panel Co-Chair Jaydira Del Rivero, MD: brnw.ch/21wSCdU

ICYMI: We released our 1st guideline to aid oncologists in managing symptoms of GEP-NETs—complex diseases that can take a toll on patient function &amp; quality of life. #ASCODailyNews has more, including comments from Expert Panel Co-Chair <a href="/JaydiDelRivero/">Jaydira Del Rivero, MD</a>: brnw.ch/21wSCdU
Society of Surgical Oncology (@socsurgonc) 's Twitter Profile Photo

Last chance to register for the SSO & AAES & NANETS Multidisciplinary Management of Neuroendocrine Liver Metastases Virtual Tumor Board! Secure your spot: ow.ly/ayTo50VJ7bI

Last chance to register for the SSO &amp; AAES &amp; NANETS Multidisciplinary Management of Neuroendocrine Liver Metastases Virtual Tumor Board! 

Secure your spot: ow.ly/ayTo50VJ7bI
NET Cancer Day (@netcancerday) 's Twitter Profile Photo

📢Watch the recording of the latest webinar from the Neuroendocrine Cancer Foundation - on updates about carcinoid heart disease. Cardiologist Dr. Prashanth Venkatesh demystifies the topic and shares the latest developments. 📱Watch here: incalliance.org/ncf-webinar-ch… #LetsTalkAboutNETs

📢Watch the recording of the latest webinar from the <a href="/NCFCancer/">Neuroendocrine Cancer Foundation</a>  - on updates about carcinoid heart disease. Cardiologist Dr. Prashanth Venkatesh demystifies the topic and shares the latest developments. 
📱Watch here: incalliance.org/ncf-webinar-ch… 
#LetsTalkAboutNETs
NANETS (@nanets1) 's Twitter Profile Photo

Nominations are open for the 2025 NANETS Awards! 🏆 Help us recognize excellence in NET research, clinical practice, mentorship, and diversity initiatives. Learn more & nominate: nanets.net/about/nanets-a… #NANETSAwards

NANETS (@nanets1) 's Twitter Profile Photo

In 2005, NET experts at ASCO sparked the idea for a dedicated society to advance neuroendocrine tumor care. That vision became NANETS—driven by innovation, collaboration, and better outcomes. 🔗 nanets.net/about/history #NETs #OncologyCare #CancerResearch #NANETS

In 2005, NET experts at ASCO sparked the idea for a dedicated society to advance neuroendocrine tumor care. That vision became NANETS—driven by innovation, collaboration, and better outcomes. 🔗 nanets.net/about/history

#NETs #OncologyCare #CancerResearch #NANETS
OncLive.com (@onclive) 's Twitter Profile Photo

Watch Namrata (Neena) Vijayvergia MD of Fox Chase Cancer Center, and Thor Halfdanarson of Mayo Clinic discuss how NETs, once considered rare, are increasingly recognized due to improved diagnostics, highlighting the importance of clinician awareness. Watch more here: hubs.li/Q03rFy3B0

NANETS (@nanets1) 's Twitter Profile Photo

On July 26, connect with the neuroendocrine cancer community at NETRF’s 2025 Know Your NETs Virtual Patient & Caregiver Conference. Register now: netrf.org/for-patients/2… #NETRF2025 #KnowYourNETs #NeuroendocrineCancer #PatientSupport #CaregiverSupport

On July 26, connect with the neuroendocrine cancer community at NETRF’s 2025 Know Your NETs Virtual Patient &amp; Caregiver Conference. Register now: netrf.org/for-patients/2… 

#NETRF2025 #KnowYourNETs #NeuroendocrineCancer #PatientSupport #CaregiverSupport
NIH (@nih) 's Twitter Profile Photo

🚨 New NIH Public Access Policy goes into effect TODAY! Research accepted for publication on July 1, 2025, must be publicly available as soon as it is published. This date was moved up from December 31, 2025, to ensure radical transparency regarding the research NIH supports.

🚨 New NIH Public Access Policy goes into effect TODAY! Research accepted for publication on July 1, 2025, must be publicly available as soon as it is published. This date was moved up from December 31, 2025, to ensure radical transparency regarding the research NIH supports.
Udhayvir Grewal (@ugrewalmd) 's Twitter Profile Photo

🚀 Excited to share our new review in npj Journals Precision Oncology: “Mucin-1: A Promising Pan-Cancer Therapeutic Target” nature.com/articles/s4169… We discuss: ✅ How aberrant MUC1 expression and glycosylation drive oncogenesis in solid and hematologic cancers ✅ The pipeline of

🚀 Excited to share our new review in <a href="/Nature_NPJ/">npj Journals</a>  Precision Oncology: “Mucin-1: A Promising Pan-Cancer Therapeutic Target”
 nature.com/articles/s4169…
We discuss:
✅ How aberrant MUC1 expression and glycosylation drive oncogenesis in solid and hematologic cancers
✅ The pipeline of
Gregory Lesinski (@lesinskilab) 's Twitter Profile Photo

Check out our new paper in Hepatology on how myeloid cells limit #immunotherapy in preclinical #cholangiocarcinoma models! Disease site matters! Collaborative effort with Chrystal Paulos and many others Winship Cancer Institute of Emory University Sidney Kimmel Comprehensive Cancer Center Vanderbilt University pubmed.ncbi.nlm.nih.gov/40590857/

NET Cancer Day (@netcancerday) 's Twitter Profile Photo

👏Thanks to Pheo Para Alliance Alliance for providing a recap of the Patient Education Day 2025 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual meeting in June. ☑️Find out more and watch the sessions recordings in YouTube in your language: incalliance.org/snmmi-patient-…

👏Thanks to <a href="/PheoPara/">Pheo Para Alliance</a> Alliance for providing a recap of the Patient Education Day 2025 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual meeting in June. 
☑️Find out more and watch the sessions recordings in YouTube in your language: incalliance.org/snmmi-patient-…
Thor Halfdanarson (@oncothor) 's Twitter Profile Photo

I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the Arvind Dasari, MD, MS et al. press. New SEER data. Increasing incidence and prevalence, owing to earlier and likely largely incidental diagnoses. Improving OS too🙂 jamanetwork.com/journals/jaman…

I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the <a href="/adasarimd/">Arvind Dasari, MD, MS</a> et al. press. New SEER data. Increasing incidence and prevalence, owing to earlier and likely largely incidental diagnoses. Improving OS too🙂

jamanetwork.com/journals/jaman…